Arbormed
PrivateLast Round
Private Placement
Apr 20, 2026
Est. Valuation
$51.16M
Total Funding Raised
$34.62M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Arbormed operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a Private Placement round in April 2026.
Arbormed is a biopharmaceutical company that develops and commercializes therapeutics for diseases with high unmet medical needs, with a focus on rare diseases and complex generics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arbormed Comparables
Compare Arbormed with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vivet Therapeutics | 79% | |
| Innorna | 79% | |
| Monopar Therapeutics | 79% |
For institutional investors. Book with your work email.
Arbormed Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Apr 20, 2026 | ||||
| Series C | Jul 1, 2024 | ||||
| Series B | Nov 1, 2021 | ||||
| Strategic | Jan 1, 2021 | ||||
| Series A | Jan 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Arbormed Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Investment Partners | Series C |
| Aion Asset Management Co., Ltd. | Series A |
| SBI Investment Korea | Series C, Series A, Series B |
| Hana Securities Co., LTD | Series A |
| Korea Investment & Securities Co., Ltd. | Series C |
| 주식회사 브로드힐벤처스 | Series A |
| 코메스인베스트먼트 | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
$1.6M raised in a private placement round.
- Jun 1, 2025
Monthly visitors grew 111% MoM, reaching 2K.
For institutional investors. Book with your work email.
Arbormed Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arbormed's valuation, stock price, and market status.
Is Arbormed a public or private company?
Arbormed is a private company.
What is the current stock price of Arbormed?
Arbormed is a private company, so its shares have no public market price. Caplight tracks Arbormed's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arbormed worth (valuation)?
Arbormed's valuation is estimated at $51.2M based on funding round data.
Can I buy Arbormed stock?
Arbormed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arbormed's last funding round?
Arbormed's most recent funding round was Private Placement on April 20, 2026.
Who are the main investors in Arbormed?
Key investors in Arbormed include Korea Investment Partners, Laplace Partners.
Will Arbormed IPO soon?
No public IPO plans have been announced for Arbormed.
How can I track Arbormed secondary market activity?
Caplight tracks bids, offers, and trades in Arbormed's shares on secondary markets.